{
  "nctId": "NCT04757584",
  "briefTitle": "Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF",
  "officialTitle": "N-of-1 Trials for Deprescribing Beta-blockers in HFpEF",
  "protocolDocument": {
    "nctId": "NCT04757584",
    "filename": "Prot_SAP_001.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2022-12-27",
    "uploadDate": "2024-01-19T14:40",
    "size": 740257,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04757584/document/Prot_SAP_001.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE4"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "CROSSOVER",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 9,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2021-04-01",
    "completionDate": "2023-04-28",
    "primaryCompletionDate": "2023-04-28",
    "firstSubmitDate": "2021-02-12",
    "firstPostDate": "2021-02-17"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Ambulatory adults ≥65 years of age with Heart Failure with Preserved Ejection Fraction (HFpEF) according to ACC/AHA guidelines: (signs and symptoms of Heart failure \\[HF\\] and ejection fraction \\[EF\\] ≥50%)\n* Taking Beta blocker\n\nExclusion Criteria:\n\n* Alternate Causes of HFpEF Syndrome:\n\n  1. Severe valvular disease\n  2. Constrictive pericarditis\n  3. High output heart failure\n  4. Infiltrative cardiomyopathy\n* Other compelling indication for beta blocker:\n\n  1. Prior EF \\< 50%\n  2. Hypertrophic cardiomyopathy\n  3. Angina symptoms\n  4. Acute coronary syndrome, myocardial infarction or coronary artery bypass surgery in prior 3 year\n  5. History of ventricular tachycardia\n  6. Atrial arrhythmia with hospitalization for rapid ventricular response, prior 1 year\n  7. Sinus tachycardia \\> 100 beats per minute (bpm), atrial arrhythmia with ventricular rate \\>90 bpm, systolic blood pressure \\> 160 mmHg\n* Clinical instability (N-of-1 trials are appropriate for stable conditions only)\n\n  1. Decompensated HF\n  2. Hospitalized in past 30 days\n  3. Medication changes or procedures in prior 14 days (to prevent confounding from other interventions), at PI discretion\n* Estimated life expectancy \\<6 months\n* Moderate-severe dementia or psychiatric disorder precluding informed consent\n* Any condition that, in Principal Investigator's opinion, makes the patient unsuitable for study participation",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "65 Years",
    "stdAges": [
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Features of a Feasible and Pragmatic Protocol for Deprescribing N-of-1 Trials in Patients With Heart Failure With Preserved Ejection Fraction, as Measured by Qualitative Interview",
        "description": "Qualitative interviews were conducted to assess the feasibility and acceptability of deprescribing N-of-1 trials and participant experiences. Directed content analysis methods were used to develop relevant categories and themes from interview transcript data. Transcripts were coded and analyzed by two team members, consulting additional members to establish consensus where needed. Inter-rater reliability between coders was established.",
        "timeFrame": "Baseline"
      },
      {
        "measure": "Features of a Feasible and Pragmatic Protocol for Deprescribing N-of-1 Trials in Patients With Heart Failure With Preserved Ejection Fraction, as Measured by Qualitative Interview",
        "description": "Qualitative interviews were conducted to assess the feasibility and acceptability of deprescribing N-of-1 trials and participant experiences. Directed content analysis methods were used to develop relevant categories and themes from interview transcript data. Transcripts were coded and analyzed by two team members, consulting additional members to establish consensus where needed. Inter-rater reliability between coders was established. The outcome measure data is the cumulative count of subjects who identified categories and themes from interview transcript data collected during the span of the outcome measure time frame, up to 6 times over 36 weeks.",
        "timeFrame": "The maximum amount of time a subject could have been assessed for this outcome measure is 6 times across 36 weeks. This outcome was measured at each end of period visit (weeks 6, 12, 18, 24, 30) and at the end of intervention (weeks 12, 18, 24, 30, or 36)"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [
        "PHASE4"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "CROSSOVER"
    },
    "overallComplexityScore": 34,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:32.162Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}